JP2022547416A5 - - Google Patents
Info
- Publication number
- JP2022547416A5 JP2022547416A5 JP2022513059A JP2022513059A JP2022547416A5 JP 2022547416 A5 JP2022547416 A5 JP 2022547416A5 JP 2022513059 A JP2022513059 A JP 2022513059A JP 2022513059 A JP2022513059 A JP 2022513059A JP 2022547416 A5 JP2022547416 A5 JP 2022547416A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- sequence number
- immune
- responsive
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962892936P | 2019-08-28 | 2019-08-28 | |
| US62/892,936 | 2019-08-28 | ||
| US202062983451P | 2020-02-28 | 2020-02-28 | |
| US62/983,451 | 2020-02-28 | ||
| PCT/EP2020/074071 WO2021038036A1 (en) | 2019-08-28 | 2020-08-28 | B CELL TARGETED PARALLEL CAR (pCAR) THERAPEUTIC AGENTS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022547416A JP2022547416A (ja) | 2022-11-14 |
| JP2022547416A5 true JP2022547416A5 (cg-RX-API-DMAC7.html) | 2023-09-04 |
| JP7723420B2 JP7723420B2 (ja) | 2025-08-14 |
Family
ID=72560541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513059A Active JP7723420B2 (ja) | 2019-08-28 | 2020-08-28 | B細胞標的化並列CAR(pCAR)治療的薬剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12534507B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4021485A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7723420B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114641308A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021038036A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019377461A1 (en) * | 2018-11-06 | 2021-05-27 | Washington University | Chimeric antigen receptor memory-like (CARML) NK cells and methods of making and using same |
| GB201900858D0 (en) * | 2019-01-22 | 2019-03-13 | Price Nicola Kaye | Receptors providing targeted costimulation for adoptive cell therapy |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| JP7723420B2 (ja) | 2019-08-28 | 2025-08-14 | キングス・カレッジ・ロンドン | B細胞標的化並列CAR(pCAR)治療的薬剤 |
| WO2021250428A1 (en) * | 2020-06-11 | 2021-12-16 | Quell Therapeutics Limited | Trem2 chimeric receptor |
| WO2022094314A1 (en) * | 2020-10-30 | 2022-05-05 | The University Of North Carolina At Chapel Hill | Dual targeting chimeric antigen receptors |
| CA3213040A1 (en) * | 2021-03-22 | 2022-09-29 | Michel Sadelain | Cd38 chimeric co-stimulating receptor and uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000034309A1 (en) * | 1998-12-04 | 2000-06-15 | Dana-Farber Cancer Institute, Inc. | Cloning and characterization of a cd2 binding protein (cd2bp2) |
| US7321026B2 (en) * | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| WO2007147901A1 (en) * | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| MX2011008611A (es) | 2009-02-16 | 2011-10-21 | Biolex Therapeutics Inc | Anticuerpos anti-cd20 humanizados y metodos de uso. |
| US9845362B2 (en) * | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| RU2729401C2 (ru) * | 2012-10-02 | 2020-08-06 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| UY35468A (es) * | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| CA2935748A1 (en) | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
| ES2751915T5 (es) * | 2014-08-15 | 2022-12-23 | Merck Patent Gmbh | Proteínas de fusión de inmunoglobulina con SIRP alfa |
| GB201503742D0 (en) | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
| GB201513540D0 (en) | 2015-07-31 | 2015-09-16 | King S College London | Therapeutic agents |
| US20190112380A1 (en) * | 2016-03-29 | 2019-04-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| BR102018008260A2 (pt) | 2017-04-24 | 2020-04-28 | Kite Pharma, Inc. | domínios de ligação ao antígeno humanizado e métodos de uso |
| CN108220247A (zh) * | 2018-03-20 | 2018-06-29 | 杭州史迪姆生物科技有限公司 | 一种双car-t细胞及其制备方法和应用 |
| CN109485732B (zh) | 2018-12-20 | 2021-09-24 | 四川大学华西医院 | 基因工程修饰的双靶点嵌合抗原受体及其用途 |
| JP7723420B2 (ja) | 2019-08-28 | 2025-08-14 | キングス・カレッジ・ロンドン | B細胞標的化並列CAR(pCAR)治療的薬剤 |
-
2020
- 2020-08-28 JP JP2022513059A patent/JP7723420B2/ja active Active
- 2020-08-28 CN CN202080076360.3A patent/CN114641308A/zh active Pending
- 2020-08-28 WO PCT/EP2020/074071 patent/WO2021038036A1/en not_active Ceased
- 2020-08-28 EP EP20774886.4A patent/EP4021485A1/en active Pending
- 2020-08-28 US US17/638,742 patent/US12534507B2/en active Active